CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma (MM), and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-MM activity both as monotherapy and in combination with other MM treatments, and has breakthrough designation on this basis.
In this issue of Clinical Cancer Research, Nighof and colleagues demonstrate the in vitro as well
as in vivo susceptibility of myeloma cells derived from lenalidomide and bortezomib-refractory MM patients to daratumumab. The authors suggest that this novel CD38 antibody may offer a new therapeutic approach for multidrug refractory MM. Importantly, they demonstrate that lenalidomide, whilst no longer active as a therapeutic agent in these patients, can still augment the anti-MM effects of daratumumab through the activation of natural killer cells in their model systems. They therefore conclude that multiply drug refractory patients may potential benefit from combination therapy with daratumumab and lenalidomide, as well as in combination with bortezomib (1).
Ideal targeted antigens for cancer immunotherapies include those molecules that demonstrate substantial overexpression on malignant cells (versus normal cells), and that are involved in key cellular growth or signaling mechanisms, with these characteristics clearly demonstrated by CD38 in MM (2-6). CD38 is a type II transmembrane glycoprotein that functions through receptor mediated adhesion signaling, as well as through ectoenzymatic activities involved in intracellular calcium mobilization (3) (4) (5) (6) . Importantly, CD38 shows low levels expression on normal hematopoietic cells and in non-hematopoietic tissues (6-7). In contrast, high and uniform expression of CD38 has been demonstrated in MM (2, (5) (6) ; this, in combination with its role in cell signaling, makes CD38 an attractive target for antibody therapy in MM (Fig. 1) .
Despite remarkable progress in the treatment of MM over the course of the last decade, the disease remains incurable, and typically follows a relapsing and ultimately refractory course, with patients requiring multiple lines of therapy (8) (9) . Treatment options for MM have expanded dramatically over the past decade to include the first-in-class proteasome inhibitor bortezomib, Set against this, daratumumab appears to offer substantial promise for the treatment of MM based on extensive preclinical findings and preliminary clinical data. It has a novel mechanism of action that results in enhanced activity in combination with existing standard of care, including first generation novel agents, such as lenalidomide and bortezomib, as well as other therapeutics (Fig. 1) . Specifically, it has also shown a strong signal in preclinical modeling with broad spectrum killing activity through CDC, ADCC, and ADC -phagocytosis (Fig. 1) . The novel target of daratumumab, namely CD38, thus appears to represent a critical pathway in MM and this in turn may result in this monoclonal antibody being less vulnerable to resistance mechanisms, not least due to the broad expression of this target in MM cells as well as in the tumor-related microenvironment. This therefore translates into potent anti-MM activity regardless of clonal heterogeneity, seen both between and within patients, and so may make this
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especially attractive as an agent for use broadly in treatment, as well as in specific high-risk subgroups of patients with molecularly-driven adverse characteristics (12) .
Daratumumab was first evaluated clinically in a phase I trial involving patients with relapsed/refractory MM (13) . The study employed a standard 3+3 dose escalation with doses ranging from 0.005 to 0.24 mg/kg. The median number of prior therapies was 5.5 and 75% of paients were refractory to both lenalidomide and bortezomib. The rate of minimal response (MR) or better was 30%, and notably the rate of MR or better among patients who received at least 4 mg/kg was 67%, with a partial response (PR) rate of 42%. Treatment-related adverse events included anemia, thrombocytopenia, and infusion reactions. These promising results led to designation of daratumamb by the US FDA as a 'breakthrough therapy,' reflecting the agent's potential to address an important area of unmet medical need.
Daratumumab was partnered with lenalidomide and dexamethasone in phase I/II trial in which patients with relapsed/refractory disease receive lenalidomide 25 mg days 1 -21 of a 28 day cycle, dexamethasone 40 mg weekly, and daratumumab 2 -16 mg/kg weekly for eight weeks, every other week for 16 weeks, and monthly thereafter (14) . This study was informed by the promising pre-clinical signal seen for this combination as described above (Fig. 1) .
In a preliminary analysis involving 20 patients, the rate of PR or better was 75%, with three patients achieving CR and six a VGPR. There were no dose limiting toxicities and the most frequent adverse events included neutropenia, thrombocytopenia and diarrhea, which generally proved manageable with dose reduction and supportive care (14) .
A phase II study of daratumumab in the 'double refractory' MM patients resistant to both immunomodulatory and proteasome inhibitor therapy has completed enrollment. Results of this Daratumumab may offer particular utility in these high risk populations due to its unique mechanism of action. Of note, the safety profile of daratumumab appears to be favorable, with few off-target effects apparent to date, despite concerns regarding potential bystander toxicity associated with its mechanism of action. Ongoing and future investigation will hopefully determine the therapeutic index of daratumumab more comprehensively in combination with other agents. Similarly, ongoing studies will also determine the tolerability of daratumumab as a long-term treatment for MM, an aspect of considerable importance in specific areas of the treatment algorithm, such as maintenance (12) . 
